menu
    • menu
    [{"orgOrder":0,"company":"Travere Therapeutics","sponsor":"Mirum Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Divestment","leadProduct":"Cholic Acid","moa":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Travere Therapeutics","amount2":0.45000000000000001,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","amount2New":0.45000000000000001,"dosageForm":"Capsule","sponsorNew":"Travere Therapeutics \/ Mirum Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Travere Therapeutics \/ Mirum Pharmaceuticals"},{"orgOrder":0,"company":"Laboratoires CTRS","sponsor":"Ethypharm","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"FRANCE","productType":"Small molecule","year":"2020","type":"Agreement","leadProduct":"Cholic Acid","moa":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Laboratoires CTRS","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"","sponsorNew":"Laboratoires CTRS \/ Ethypharm","highestDevelopmentStatusID":"12","companyTruncated":"Laboratoires CTRS \/ Ethypharm"}]

    Find Clinical Drug Pipeline Developments & Deals for Cholic Acid

    Menu

    Cholic Acid

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Travere Therapeutics

                            U.S.A arrow
                            PharmaVenue
                            Not Confirmed

                            Travere Therapeutics

                            U.S.A arrow
                            PharmaVenue
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Cholic Acid

                            Therapeutic Area : Genetic Disease

                            Study Phase : Approved

                            Sponsor : Mirum Pharmaceuticals

                            Deal Size : $445.0 million

                            Deal Type : Divestment

                            DEALS_DEV arrow-down

                            Travere Therapeutics Enters Agreement to Sell its Bile Acid Product Portfolio for the Treatment of Rare Liver ...

                            Details : Under the agreement, Mirum will purchase Travere’s bile acid product portfolio including, Cholbam, indicated for the treatment of bile acid synthesis disorders and Chenodal, indicated for the treatment of radiolucent stones in the gallbladder.

                            Brand Name : Cholbam

                            Molecule Type : Small molecule

                            Upfront Cash : $210.0 million

                            July 17, 2023

                            Lead Product(s) : Cholic Acid

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Approved

                            Sponsor : Mirum Pharmaceuticals

                            Deal Size : $445.0 million

                            Deal Type : Divestment

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Laboratoires CTRS

                            Country arrow
                            PharmaVenue
                            Not Confirmed

                            Laboratoires CTRS

                            Country arrow
                            PharmaVenue
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Cholic Acid

                            Therapeutic Area : Genetic Disease

                            Study Phase : Approved

                            Sponsor : Ethypharm

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Ethypharm, CTRS Partner to Register Orphacol® in China

                            Details : Under the agreement, CTRS has granted Ethypharm exclusive rights to distribute Orphacol (cholic acid) in China. It is indicated for the two rare inborn errors of primary bile acid synthesis.

                            Brand Name : Orphacol

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            November 10, 2020

                            Lead Product(s) : Cholic Acid

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Approved

                            Sponsor : Ethypharm

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth